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T
he superb liver-to-lesion contrast of MRI and its ability to display the same lesion enhancement patterns as CT combined with its lack of ionizing radiation have led to this modality being widely accepted for assessing the broad spectrum of hepatic abnormalities. Moreover, hepatocyte-specific contrast agents are now available.
The differential diagnosis of hypervascular hepatic lesions depends on the status of the remainder of the organ. If the liver is normal, the most common causes of hypervascular liver lesions are hemangioma, focal nodular hyperplasia (FNH), adenoma, and hypervascular metastasis. In the presence of chronic liver disease, the likely causes include vascular shunts (transient hepatic enhancement difference [THED]), regenerative nodules, dysplastic nodules, and hepatocellular carcinoma (HCC) ( Table 1) .
MRI Techniques Sequences
At most institutions, the following sequences are used as the standard technique for MRI of the liver: 1. Coronal ultrafast spin-echo sequence (single breath-hold), which serves as a localizer and provides an overview of the anatomy. T2-weighted images help characterize lesions (e.g., cyst, hemangioma, FNH, HCC). 2. Axial fast spin-echo (T2-weighted) images through the liver. Fat-saturated (frequency selective) images increase the conspicuity of liver lesions. 3. Axial 2D dual spoiled gradient-recalled echo sequence (SPGR) (both out-of-phase and inphase imaging during a single breath-hold). This provides T1 information and helps detect focal or diffuse fatty infiltration (loss of signal on out-of-phase sequence) (Fig. 1 ). This sequence also can assess for presence of fat within a liver lesion (e.g., adenoma, HCC, metastases from a clear cell cancer) and detect iron deposition in hemochromatosis or hemosiderosis (loss of signal on in-phase or longer echo sequence) (Fig. 2 ). 4. Volume interpolated gradient-echo with fat saturation. This sequence is valuable for the detection and characterization of lesions on the basis of their enhancement patterns. In addition to an unenhanced image, repeat images are acquired at multiple phases after the injection of gadolinium-early arterial and arterial (time determined by test bolus), portal venous (40-60 seconds), and delayed (varies from 90 seconds to several minutes). Additional delayed imaging is performed if gadoxetate disodium (Eovist, Bayer HealthCare) or gadobenate dimeglumine is administered. These agents are used for further characterization of hypervascular liver lesions in general and in particular to confirm that the lesion represents focal nodular hyperplasia (discussed later). The unenhanced images can be subtracted from 
Contrast Agents
Gadolinium chelates without specific distribution in biologic tissues and primarily confined to extracellular spaces have been commercially available since 1986. Paramagnetic gadolinium shortens the tissue-specific relaxation times, leading to an increase in hepatic tissue signal intensities, particularly on T1-weighted images. Rapid redistribution of gadolinium chelates from intravascular to extracellular spaces requires IV injection of this contrast agent in a small-volume bolus (up to 2 mL/s) with an individually calculated dose of 0.1-0.2 mmol/kg of body weight.
Hepatocyte-targeted contrast agents are characterized by active transport of the chelates into the hepatocytes, where they are further metabolized and partly eliminated through the biliary system. Thus, they permit assessment of both the liver parenchyma and the biliary system on T1-weighted images. The most commonly used hepatocyte-selective contrast materials are gadolinium-based agents such as gadoxetate disodium and gadobenate dimeglumine. Gadobenate dimeglumine has 5% excretion via the biliary tract, and delayed imaging is performed in 1 hour. Gadoxetate disodium has 50% excretion via the biliary tract, and delayed imaging is performed after 20 minutes. In addition to allowing imaging during the arterial phase, the redistribution or portal venous phase, and the equilibrium or hepatic venous phase (a feature comparable with those of the other gadolinium chelates), these newer agents also contribute a hepatocyte phase to the protocol for contrast-enhanced liver imaging. 
Hemangioma
A hemangioma is a well-circumscribed mass of blood-filled spaces lined by endothelium on a thin fibrous stroma. Hemangiomas occur more frequently in women, are generally asymptomatic, and are discovered incidentally. MRI is the most sensitive and specific diagnostic study for hemangiomas, with one series reporting specificity of 100% in differentiating hemangiomas from metastases. On T2-weighted images, they are markedly hyperintense and have cystlike signal intensity (Figs. 3A, 3B , 4A, 4B, 5A, and 5B). In addition, hemangiomas retain their high signal intensity on heavily T2-weighted images with TE greater than 112 ms, whereas malignant neoplasms lose their high signal on these sequences. On T1-weighted images, hemangiomas are hypointense relative to the liver (Fig. 3C, 4C , and 5C).
The three distinct enhancement patterns of hemangiomas after contrast injection generally follow those of the blood pool. The first pattern, which is characterized by immediate uniform enhancement, is typical of small capillary hemangiomas (< 1.5 cm) (Figs. 3D-3F ). In the second and most common pattern (77% of cases), the hemangioma generally appears as a well-circumscribed hepatic mass with peripheral, nodular, and interrupted enhancement that can be greater than or equal to that of the blood pool and progresses centripetally to uniform enhancement (Figs. 4D-4G ). In the third pattern, there is also peripheral nodular enhancement with centripetal progression but also persistent hypointensity of the central portion of the lesion (giant hemangiomas > 5 cm) (Figs. 5D-5G ). 
Focal Nodular Hyperplasia
FNH is a benign tumor that is thought to represent a hyperplastic response of the hepatic parenchyma to a preexisting arterial malformation. It is most common in women of reproductive age but can occur in men and children. After hemangiomas, most incidental hypervascular liver lesions in noncirrhotic livers represent FNH and not adenoma. Histologically, FNH contains hyperplastic hepatocytes and small bile ductules surrounding a central fibrous scar. The Kupffer cells are present in relatively high numbers in FNH compared with hepatic adenoma and HCC. A helpful morphologic feature for distinguishing FNH from adenoma is the margin of the lesion, which is typically ill-defined or lobulated in FNH whereas the margin is usually smooth and well circumscribed in adenomas.
On MRI, FNH is generally isointense relative to the liver on T1-weighted images (Fig. 6C ) and isointense to slightly hyperintense on T2-weighted images (Figs. 6A and 6B ). The classic central scar is T1 hypointense and T2 hyperintense because of the presence of blood vessels, bile ductules, and edema within myxomatous tissue and typically shows delayed enhancement. On dynamic contrast-enhanced images (Figs. 6D-6G ), FNH shows markedly homogeneous arterial phase enhancement that becomes isointense during the portal venous phase. MRI with a hepatocyte-specific contrast agent (Eovist or gadobenate dimeglumine) helps confirm the hepatocellular origin of the mass. On 20-minute delayed contrast-enhanced images, FNH appears isointense to the background liver because of the presence of bile ducts (Fig. 6G ).
Hepatic Adenoma
Hepatic adenoma is a very rare benign neoplasm that is most commonly seen in women taking oral contraceptives. The prevalence of this tumor increases with the duration of oral contraceptive use and the size of the estrogen dose. Although adenomas are typically solitary, they are multiple in about 20% of cases, especially in patients with glycogen storage disease or those who have used anabolic steroids.
Pathologically, a hepatic adenoma is composed of benign hepatocytes that are arranged in large plates or cords without acinar architecture. The hepatocytes are separated by dilated sinusoids, which may cause the hypervascularity in this tumor. The absence of bile ducts is an important histologic means of distinguishing an adenoma from FNH. An accurate diagnosis of hepatic adenoma is essential for clinical management because of the tendency of the lesion to spontaneously rupture or hemorrhage as well as the potential for malignant transformation.
On MRI, adenomas have variable signal intensity but can show hyperintense foci on unenhanced T1-weighted images secondary to hemorrhage or intracellular lipid. The visualization of fat within the lesion on fat-suppressed or opposed-phase T1-weighted images helps distinguish an adenoma from FNH (Figs. 7A and 7B). On T2-weighted images, hepatic adenomas can have variable signal intensity, but they are often mildly hyperintense relative to the liver (Fig. 7C) . On dynamic contrast-enhanced images, adenomas show heterogeneous hypervascularity during the arterial phase. These masses often show no washout of contrast material, becoming isointense to the liver parenchyma on portal venous and subsequent dynamic series (Figs. 7D-7F ), and they may have a delayed-enhancing pseudocapsule. Adenomas do not take up hepatocyte-specific contrast material and therefore appear hypointense to liver on delayed images when these agents are used (Fig. 7G) .
Hepatocellular Carcinoma
HCC is the most common primary malignancy of the liver. It is often associated with underlying hepatic cirrhosis, which may be secondary to infectious (hepatitis), toxic (alcohol), or metabolic (e.g., hemochromatosis, Wilson disease, α 1 -antitrypsin deficiency syndrome) processes. It is essential to accurately differentiate frankly malignant HCC from cirrhotic nodules ranging from benign regenerative to premalignant dysplasia, although this can be challenging because of considerable overlap in imaging and histologic features.
On T2-weighted images, HCC is usually hyperintense (Figs. 8A, 8B , and 9A).On unenhanced T1-weighted images, HCC is often isointense to liver, whereas larger lesions may be hyperintense secondary to their lipid, copper, or glycogen contents (Fig. 8C and 9D ). Highgrade dysplastic nodules and small HCC may have a nodule-within-a-nodule appearance, especially if a focus of HCC originates in a larger dysplastic nodule. Fatty metamorphosis in a cirrhotic nodule is highly suspicious for HCC (Figs. 9 B and 9C) . In cirrhotic patients, any Khosa et al. C-G, On axial nonfatsuppressed T2weighted image (C), lesion shows subtle high signal intensity compared with background liver (circle). Unenhanced (D) and contrastenhanced volume interpolated gradientecho with fat saturation (E) images after administration of gadoxetate disodium (Eovist, Bayer HealthCare) show that lesion has heterogeneous avid enhancement during arterial phase (E) and becomes isointense to mildly hypointense to liver on portal venous phase (F). On 20minute delayed image (G), lesion is hypointense to background liver (i.e., no retention of contrast material in adenoma), feature that differentiates it from focal nodular hyperplasia.
Khosa et al. hypervascular liver mass other than a hemangioma, which is larger than 2 cm and shows increased T2 signal similar to that of the spleen, is highly suspicious for HCC. With dynamic contrast-enhanced imaging, small lesions (< 2 cm) may show homogeneous intense enhancement during the arterial phase. Larger lesions more often show heterogeneous enhancement. During the portal venous and equilibrium phases, HCC shows a rapid washout The capsule, if present, is typically thin and discontinuous, hypointense to liver on both T1-weighted images and T2-weighted images, and shows progressive delayed enhancement. Vascular shunts, THED, regenerative nodules, and dysplastic nodules are the more common lesions that require differentiation from HCC in patients with chronic liver disease. Vascular shunts and THED can also be seen in the absence of cirrhosis but are much more commonly encountered in the setting of cirrhosis. The liver has a dual blood supply, with approximately 75% of its flow from the portal vein and 25% from the hepatic artery. On contrast-enhanced MRI, the conduits supplying blood to the liver parenchyma (i.e., hepatic artery and portal vein pathways) are opacified tens of seconds apart, resulting in a variety of enhancement patterns if there is not uniform flow across the liver parenchyma. The hepatic arterial flow varies inversely with portal venous flow, so that any condition that decreases portal flow locally will result in an increase in the arterial flow. THEDs are the imaging manifestation of regional variations in the balance between hepatic arterial and portal venous inflow that result in local heterogeneity and masslike appearance in some cases on contrast-enhanced MRI (Figs. 10 and 11 ). They also can result from nontumorous arterioportal shunts or obstruction of parenchymal portal venous flow and may cause arterial phase enhancement that can mimic an underlying mass. These arterioportal shunts in the setting of cirrhosis are a common cause of concern for HCC on imaging. A vascular shunt such as THED is typically geographically shaped, located peripherally, and isointense to liver on all unenhanced sequences (Figs. 10A, 10B , 11A, and 11B). The lesion is hypervascular on arterial phase images (Figs. 10C, 11C , and 11D) and becomes isointense to liver on delayed dynamic images, features that help distinguish arterioportal shunts from HCC (Figs. 10D, 10E , 11E, and 11F). Regenerative nodules result from localized proliferation of hepatocytes and their supporting stroma. These are simply the background nodules of cirrhosis, are typically small and isointense to liver on all sequences, and show a degree of enhancement similar to adjacent liver A and B, Axial T2weighted (A) and unenhanced volume interpolated gradientecho with fat saturation (B) images do not show any definite lesion in segment V of liver. C-F, On arterial phase contrastenhanced image (C) after administration of gadopentetate dimeglumine, there is avid enhancement of hepatic artery pseudoaneurysm (arrow) and associated THED due to arterioportal fistula (arrowheads). On subsequent dynamic images (E and F), pseudoaneurysm (arrow) follows enhancement similar to that of aorta, and THED (arrowheads) almost becomes isointense to background liver. Vasculature is seen traversing THED on all unenhanced and contrastenhanced images, which confirms that this is not real lesion and represents perfusion anomaly.
Khosa et al. parenchyma, If they contain iron and or copper, the nodules may be low signal intensity on gradient-echo sequences (siderotic nodules) (Fig. 12) . Dysplastic nodules are composed of hepatocytes that show histologic characteristics of abnormal growth, may show hypervascularity without washout or a capsule (unlike HCC), and are generally T2 hypointense (Fig. 12 ). Fibrolamellar carcinoma, unlike HCC, has no association with underlying chronic liver disease, and its cause is unknown. At presentation, fibrolamellar carcinoma generally presents as a large mass (5-20 cm) with well-defined and lobulated margins. On MRI, fibrolamellar carcinoma is usually hypo-to isointense relative to the liver parenchyma on unenhanced T1-weighted images and slightly hyperintense on T2-weighted images; foci of necrosis may be seen as areas of high T2 signal. The central scar of fibrolamellar carcinoma has low signal intensity on both T1-and T2-weighted images in contrast to FNH, which has a high signal intensity scar on T2-weighted images. In addition, the central scar of fibrolamellar carcinoma shows minimal or no enhancement.
Hypervascular Metastases
Metastases are the most common malignant hepatic tumor. Although most commonly multifocal, discrete lesions may sometimes manifest as a solitary mass or as confluent masses. All hepatic tumors are preferentially supplied by the hepatic artery. Consequently, the degree of enhancement depends on the briskness of the underlying hepatic vascular supply. Metastases generally are irregular with indistinct margins. On T2-weighted images, hypervascular metastases are usually hyperintense and may be cystic or necrotic (Figs. 13A, 14A , and 14B). On unenhanced T1-weighted images, hypervascular metastases generally are moderately hypointense relative to normal liver (Fig. 13 B) . However, hemorrhagic metastases (kidney, melanoma) may be hyperintense to liver on unenhanced and contrast-enhanced images (Figs. 14C-14F ). Perilesional fat deposition, which has been described as characteristic of hepatic metastases from a primary pancreatic insulinoma, is thought to be related to the effects of insulin on inhibiting fatty acid oxidation and promoting hepatocyte triglyceride accumulation. Hypovascular metastases show decreased enhancement relative to normal liver and are most conspicuous on portal venous phase images. Hypervascular metastases enhance earlier and are best seen on arterial phase images. They also show perilesional rim enhancement and irregular washout on delayed images (Fig. 13E) . Hypervascular metastases typically arise from primary neuroendocrine tumors (pancreatic islet cell tumor, carcinoid tumor, and pheochromocytoma), renal cell carcinoma, thyroid carcinoma, choriocarcinoma, or melanoma. 
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Vascular Fistulas Mimicking Hypervascular Lesions
Hypervascular liver lesions can be seen in cases of congenital or acquired or iatrogenic arteriovenous or venovenous fistulas. Multiplanar reformats and maximum-intensity-projection images are extremely helpful for assessment of these lesions (Figs. 15 and 16 ).
Conclusions
As the role of MRI for clinical hepatic imaging continues to evolve, keeping abreast of newer pulse sequences and contrast agents can be daunting as well as confusing. Because the liver can be involved primarily or secondarily by numerous vascular, metabolic, infectious, and neoplastic processes, the patient's clinical history can have a considerable impact on the imaging differential diagnosis. Thus, a systematic approach that makes use of a decision algorithm based on the presence or absence of chronic liver disease and the distinguishing imaging characteristics of various lesions is helpful in formulating a more specific diagnosis for a hypervascular liver mass (Table 2) . Follow-up of indeterminate liver lesions depends on institutional protocol and presence or absence of underlying liver disease or primary malignancy (Fig. 17) . 
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